Device Trial Radar · NCT01294150
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
Last checked: Nov 19, 2026Latest source record: Sep 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
206
Actual
Start
Feb 2011
Primary completion
Feb 2013
Study completion Jul 5, 2017
Sponsor
- Lead sponsor
- NeoTract, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Feb 11, 2011
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- Who can join
- Male only, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety and effectiveness of the UroLift(R) System when used in subjects with symptomatic benign hyperplasia (BPH). Primary effectiveness will be achieved by looking at the improvement of International Prostate Symptom Score (IPSS) and safety will be reviewed based on pertinent adverse events.
Conditions
- Benign Prostatic Hyperplasia
Interventions
UroLift SystemDevice
The NeoTract UroLift System is a medical device approved for sale in the United States, European Union, and several other countries (see www.urolift.com). It was developed for the treatment of lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
CystoscopyOther
The Control Group will undergo cystoscopy.
CrossoverDevice
Subjects crossed over and received the UroLift System from the Control Group.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Collection of Post-treatment Catheterization for SafetyTime frame: Cath within first 3 days post-procedure which extended beyond 7 days, up to 12 days
- Comparison of IPSS for EfficacyTime frame: 3 month
- Mean UroLift Improvement in IPSS at 12 MonthsTime frame: 12 months
Locations
19 sites in 3 countries. Site status is shown where the registry gives one.
Genesis Research LLC
San Diego, California
Shahram S. Gholami MD - A Professional Corp.
San Jose, California
Urology Associates of Denver
Englewood, Colorado
16 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.